We are live on ! Find out more
PMCB icon

PharmaCyte Biotech
PMCB

22 hedge funds and large institutions have $4.42M invested in PharmaCyte Biotech in 2021 Q3 according to their latest regulatory filings, with 22 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more call options, than puts

Call options by funds: $234K | Put options by funds: $140K

6.74% more ownership

Funds ownership: 0% → 6.74% (+6.7%)

Holders
22
Holders Change
+22
Holders Change %
–
% of All Funds
0.39%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
22
Increased
–
Reduced
–
Closed
–
Calls
$234K
Puts
$140K
Net Calls
+$94K
Net Calls Change
+$94K

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$3.55M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$470K
3
SSA
Schonfeld Strategic Advisors
New York
+$310K
4
SFI
Susquehanna Fundamental Investments
Pennsylvania
+$175K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$164K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$3.2M +$3.55M +1,010,146 New
T. Rowe Price Associates
2
T. Rowe Price Associates
Maryland
$424K +$470K +133,600 New
SSA
3
Schonfeld Strategic Advisors
New York
$280K +$310K +88,200 New
SFI
4
Susquehanna Fundamental Investments
Pennsylvania
$158K +$175K +49,700 New
Geode Capital Management
5
Geode Capital Management
Massachusetts
$147K +$164K +46,610 New
NP
6
NorthRock Partners
Minnesota
$118K +$131K +37,164 New
SC
7
Shay Capital
New York
$46K +$51.3K +14,606 New
TRCT
8
Tower Research Capital (TRC)
New York
$22K +$24.9K +7,070 New
UBS Group
9
UBS Group
Switzerland
$11K +$12K +3,401 New
Osaic Holdings
10
Osaic Holdings
Arizona
$6K +$6.2K +1,763 New
Morgan Stanley
11
Morgan Stanley
New York
$4K +$4.74K +1,349 New
Fidelity Investments
12
Fidelity Investments
Massachusetts
$2K +$1.76K +500 New
Royal Bank of Canada
13
Royal Bank of Canada
Ontario, Canada
$2K +$2.33K +662 New
APC
14
Aspire Private Capital
North Carolina
$1K +$1.41K +400 New
KFS
15
Kelly Financial Services
Massachusetts
$831 +$921 +262 New
FDCDDQ
16
Federation des caisses Desjardins du Quebec
Quebec, Canada
$22 +$25 +7 New
HI
17
Harbour Investments
Wisconsin
– +$11 +3 New
TWA
18
TCI Wealth Advisors
Arizona
– +$11 +3 New
COCM
19
Charter Oak Capital Management
New Hampshire
– +$70 +20 New
Wells Fargo
20
Wells Fargo
California
– +$91 +26 New
Bank of America
21
Bank of America
North Carolina
– +$204 +58 New
CG
22
Cutler Group
California
– +$274 +78 New

PMCB Hedge Fund Activity: Q3 2021 in Review

22 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in PharmaCyte Biotech (PMCB) for Q3 2021, worth a combined $4.42M.

Buyers outnumbered sellers: 22 funds opened new PMCB positions and 0 closed out — a net gain of 22 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Sabby Management, opening a new position worth an estimated $3.55M.

  • 22 institutional investors held PharmaCyte Biotech (PMCB) as of Q3 2021, up from 0 in Q2 2021.
  • Funds reported $4.42M of PharmaCyte Biotech stock for Q3 2021.
  • 22 funds opened new PharmaCyte Biotech positions in Q3 2021 and 0 closed out, a net change of +22 holders.
  • The largest PharmaCyte Biotech buyer in Q3 2021 was Sabby Management, an estimated $3.55M added.

Based on aggregated 13F filings for Q3 2021.